Universal Beteiligungs und Servicegesellschaft mbH Takes $12 Million Position in Exelixis, Inc. (NASDAQ:EXEL)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 360,292 shares of the biotechnology company's stock, valued at approximately $11,998,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.13% of Exelixis at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Coppell Advisory Solutions LLC acquired a new stake in Exelixis in the 4th quarter worth about $25,000. Colonial Trust Co SC lifted its holdings in shares of Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 765 shares during the period. Principal Securities Inc. lifted its holdings in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 373 shares during the period. Kestra Investment Management LLC acquired a new stake in shares of Exelixis in the fourth quarter worth approximately $39,000. Finally, Crowley Wealth Management Inc. purchased a new stake in Exelixis in the fourth quarter valued at approximately $50,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Exelixis Stock Performance

Shares of NASDAQ EXEL traded up $0.21 during midday trading on Wednesday, reaching $42.88. 554,180 shares of the company's stock were exchanged, compared to its average volume of 2,320,055. Exelixis, Inc. has a 52-week low of $21.36 and a 52-week high of $48.85. The business's fifty day moving average price is $38.68 and its two-hundred day moving average price is $36.49. The stock has a market capitalization of $11.69 billion, a PE ratio of 24.23, a price-to-earnings-growth ratio of 1.13 and a beta of 0.28.

Analyst Ratings Changes

Several brokerages have recently issued reports on EXEL. Piper Sandler boosted their price objective on shares of Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Wall Street Zen downgraded Exelixis from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 15th. HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Exelixis in a research note on Thursday, March 27th. Guggenheim set a $45.00 price objective on Exelixis and gave the company a "buy" rating in a research note on Thursday, May 15th. Finally, Citigroup boosted their target price on Exelixis from $45.00 to $56.00 and gave the stock a "buy" rating in a report on Thursday, May 15th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.94.

Insiders Place Their Bets

In related news, CFO Christopher J. Senner sold 100,000 shares of the company's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $46.00, for a total transaction of $4,600,000.00. Following the sale, the chief financial officer now directly owns 967,842 shares of the company's stock, valued at approximately $44,520,732. This represents a 9.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CMO Amy C. Peterson sold 72,776 shares of Exelixis stock in a transaction on Friday, May 16th. The stock was sold at an average price of $45.47, for a total transaction of $3,309,124.72. Following the completion of the transaction, the chief marketing officer now directly owns 465,393 shares of the company's stock, valued at approximately $21,161,419.71. This represents a 13.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 431,740 shares of company stock valued at $19,894,998 in the last ninety days. Corporate insiders own 2.85% of the company's stock.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.